Additional data supporting utility of PAM50 gene signature for breast cancer to be pr
 

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that researchers will present additional evidence for the potential utility of profiling breast cancer based on the PAM50 gene signature at the 2011 American Society of Clinical Oncology annual meeting taking place in Chicago, Illinois from June 3-7.

More...